Vera's Trutakna Shows Kidney Function Stability in Phase 3 IgAN Trial
New phase 3 results position Vera's Trutakna as a direct competitor to Otsuka's Voyxact in the IgA nephropathy market.
Vera Therapeutics has reported phase 3 data for its investigational therapy Trutakna in patients with IgA nephropathy (IgAN). The results indicate that the drug successfully stabilizes kidney function, a key goal in treating this progressive kidney disease.
The outcome echoes an earlier clinical success from Otsuka's Voyxact, which also demonstrated stabilization of kidney function in IgAN. This similarity positions Trutakna as a direct rival to Voyxact in a market that is rapidly evolving.
With both therapies showing comparable efficacy, competition is expected to intensify as companies seek to capture share in the IgAN treatment landscape. The new data adds momentum to Vera's development program and underscores the growing number of options for patients.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.